Jolanda de Vries

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6536515/publications.pdf

Version: 2024-02-01

226 papers	17,136 citations	13099 68 h-index	17105 122 g-index
232 all docs	232 docs citations	232 times ranked	19430 citing authors

#	Article	IF	Citations
1	Metabolomic and lipidomic signatures associated with activation of human cDC1 (BDCA3⁺/CD141⁺) dendritic cells. Immunology, 2022, 165, 99-109.	4.4	8
2	Immunological responses to adjuvant vaccination with combined CD1c⁺ myeloid and plasmacytoid dendritic cells in stage III melanoma patients. OncoImmunology, 2022, 11, .	4.6	14
3	Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion. , 2022, 10, e004309.		8
4	A fluorogenic probe for granzyme B enables in-biopsy evaluation and screening of response to anticancer immunotherapies. Nature Communications, 2022, 13, 2366.	12.8	26
5	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
6	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology, 2022, 11, .	4.6	54
7	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. OncoImmunology, 2022, 11, .	4.6	3
8	Immune cell composition in the endometrium of patients with a complete molar pregnancy: Effects on outcome. Gynecologic Oncology, 2021, 160, 450-456.	1.4	4
9	Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients. OncoImmunology, 2021, 10, 1935557.	4.6	17
10	PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses. Frontiers in Immunology, 2021, 12, 641703.	4.8	21
11	Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients. Journal of Allergy and Clinical Immunology, 2021, 148, 1030-1040.	2.9	25
12	Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3â€dioxygenase 1 with functional effects on T cell priming. European Journal of Immunology, 2021, 51, 1494-1504.	2.9	11
13	LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma. Immuno, 2021, 1, 67-77.	1.5	3
14	Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome. Cancers, 2021, 13, 2345.	3.7	3
15	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
16	Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. Cancers, 2021, 13, 2249.	3.7	28
17	Recent Advances and Future Perspective of DC-Based Therapy in NSCLC. Frontiers in Immunology, 2021, 12, 704776.	4.8	13
18	Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. Cancers, 2021, 13, 4660.	3.7	2

#	Article	IF	Citations
19	The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer. Frontiers in Immunology, 2021, 12, 724883.	4.8	19
20	In Vivo PET Imaging of Monocytes Labeled with [89Zr]Zr-PLGA-NH2 Nanoparticles in Tumor and Staphylococcus aureus Infection Models. Cancers, 2021, 13, 5069.	3.7	4
21	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. Frontiers in Immunology, 2021, 12, 768957.	4.8	22
22	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. BMJ Open, 2021, 11, e050725.	1.9	21
23	Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer. Frontiers in Immunology, 2021, 12, 802877.	4.8	5
24	Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder. Cancers, 2020, 12, 2692.	3.7	29
25	What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. Cytotherapy, 2020, 22, 388-397.	0.7	29
26	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. Frontiers in Oncology, 2020, 10, 536700.	2.8	4
27	Subsets of CD1c+ DCs: Dendritic Cell Versus Monocyte Lineage. Frontiers in Immunology, 2020, 11, 559166.	4.8	41
28	The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture. Nature Communications, 2020, 11, 2749.	12.8	51
29	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. OncoImmunology, 2020, 9, 1774298.	4.6	22
30	Lactate dehydrogenase: a marker of diminished antitumor immunity. OncoImmunology, 2020, 9, 1731942.	4.6	107
31	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. OncoImmunology, 2020, 9, 1738814.	4.6	13
32	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. Cancer Immunology, Immunotherapy, 2020, 69, 477-488.	4.2	42
33	Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer. Frontiers in Immunology, 2020, 11, 631713.	4.8	27
34	Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination. Cell Reports, 2020, 30, 1027-1038.e4.	6.4	29
35	STAT Family Protein Expression and Phosphorylation State during moDC Development Is Altered by Platinum-Based Chemotherapeutics. Journal of Immunology Research, 2019, 2019, 1-12.	2.2	11
36	Dendritic Cells Require PINK1-Mediated Phosphorylation of BCKDE1Î± to Promote Fatty Acid Oxidation for Immune Function. Frontiers in Immunology, 2019, 10, 2386.	4.8	20

#	Article	IF	Citations
37	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. , 2019, 7, 302.		72
38	Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites. Frontiers in Immunology, 2019, 9, 3156.	4.8	18
39	Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Annals of Oncology, 2019, 30, 1370-1380.	1.2	171
40	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
41	Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy. Annals of Surgical Oncology, 2019, 26, 3945-3952.	1.5	24
42	Multicore Liquid Perfluorocarbonâ€Loaded Multimodal Nanoparticles for Stable Ultrasound and ¹⁹F MRI Applied to In Vivo Cell Tracking. Advanced Functional Materials, 2019, 29, 1806485.	14.9	47
43	Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity. Frontiers in Immunology, 2019, 10, 824.	4.8	29
44	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. Clinical and Translational Oncology, 2019, 21, 774-780.	2.4	7
45	PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. Translational Oncology, 2019, 12, 361-367.	3.7	33
46	Customizing poly(lactic-co-glycolic acid) particles for biomedical applications. Acta Biomaterialia, 2018, 73, 38-51.	8.3	236
47	Design of triphasic poly(lactic-co-glycolic acid) nanoparticles containing a perfluorocarbon phase for biomedical applications. RSC Advances, 2018, 8, 6460-6470.	3.6	14
48	Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. Journal of Immunology, 2018, 200, 347-354.	0.8	181
49	Human Dendritic Cell Subsets Undergo Distinct Metabolic Reprogramming for Immune Response. Frontiers in Immunology, 2018, 9, 2489.	4.8	86
50	Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report. Frontiers in Oncology, 2018, 8, 562.	2.8	11
51	BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?. Vaccines, 2018, 6, 65.	4.4	13
52	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. Frontiers in Immunology, 2018, 9, 2265.	4.8	107
53	Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month Randomized Controlled Trial. Cancer Investigation, 2018, 36, 371-377.	1.3	3
54	Clinically-Applicable Perfluorocarbon-Loaded Nanoparticles For In vivo Photoacoustic, ¹⁹F Magnetic Resonance And Fluorescent Imaging. Nanotheranostics, 2018, 2, 258-268.	5.2	29

#	Article	IF	Citations
55	Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG. Frontiers in Immunology, 2018, 9, 1412.	4.8	40
56	Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System. International Journal of Molecular Sciences, 2018, 19, 273.	4.1	22
57	Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells. Cancer Immunology, Immunotherapy, 2018, 67, 1425-1436.	4.2	15
58	The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. Molecular Imaging and Biology, 2018, 20, 696-704.	2.6	30
59	Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells. Nature Communications, 2018, 9, 3317.	12.8	116
60	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5036-5036.	1.6	2
61	Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.. Journal of Clinical Oncology, 2018, 36, 219-219.	1.6	2
62	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. Journal of Clinical Oncology, 2018, 36, 248-248.	1.6	5
63	Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients. Scientific Reports, 2017, 7, 43486.	3.3	16
64	Migrating into the Tumor: a Roadmap for T Cells. Trends in Cancer, 2017, 3, 797-808.	7.4	230
65	Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. Cancer Letters, 2017, 403, 159-164.	7.2	37
66	Multispectral imaging for highly accurate analysis of tumourâ€infiltrating lymphocytes in primary melanoma. Histopathology, 2017, 70, 643-649.	2.9	14
67	Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy. Oncotarget, 2017, 8, 19879-19893.	1.8	20
68	Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. Oncotarget, 2017, 8, 54434-54443.	1.8	13
69	Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. Oncotarget, 2017, 8, 67439-67456.	1.8	15
70	Isolation of Mononuclear Cell Populations from Ovarian Carcinoma Ascites. Bio-protocol, 2017, 7, e2219.	0.4	5
71	A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets. Mediators of Inflammation, 2016, 2016, 1-11.	3.0	57
72	Innate Lymphoid Cells in Tumor Immunity. Biomedicines, 2016, 4, 7.	3.2	26

#	Article	IF	Citations
73	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. Journal of Immunotherapy, 2016, 39, 241-248.	2.4	26
74	Circulating Apoptotic Microparticles in Systemic Lupus Erythematosus Patients Drive the Activation of Dendritic Cell Subsets and Prime Neutrophils for NETosis. Arthritis and Rheumatology, 2016, 68, 462-472.	5.6	131
75	Dendritic Cellâ€"Based Immunotherapy: State of the Art and Beyond. Clinical Cancer Research, 2016, 22, 1897-1906.	7.0	295
76	Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunology, Immunotherapy, 2016, 65, 1249-1259.	4.2	67
77	T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. Cancer Research, 2016, 76, 3496-3506.	0.9	33
78	Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity. OncoImmunology, 2016, 5, e1227902.	4.6	26
79	Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. Ophthalmology, 2016, 123, 2265-2267.	5.2	44
80	Human CD1c⁺ DCs are critical cellular mediators of immune responses induced by immunogenic cell death. OncoImmunology, 2016, 5, e1192739.	4.6	74
81	Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function. Cell Reports, 2016, 16, 2953-2966.	6.4	72
82	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. Journal of Translational Medicine, 2016, 14, 88.	4.4	10
83	Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. OncoImmunology, 2016, 5, e1191732.	4.6	17
84	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. OncoImmunology, 2016, 5, e1201625.	4.6	21
85	Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. Human Vaccines and Immunotherapeutics, 2016, 12, 2523-2528.	3.3	15
86	Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. Cancer Research, 2016, 76, 4332-4346.	0.9	93
87	Cancer vaccine triggers antiviral-type defences. Nature, 2016, 534, 329-331.	27.8	27
88	Improving cancer immunotherapy by targeting the STATe of MDSCs. OncoImmunology, 2016, 5, e1196312.	4.6	50
89	Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. Familial Cancer, 2016, 15, 289-296.	1.9	13
90	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. OncoImmunology, 2016, 5, e1057673.	4.6	67

#	Article	IF	Citations
91	Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunology, Immunotherapy, 2016, 65, 327-339.	4.2	50
92	Long-lasting multifunctional CD8⁺T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. OncoImmunology, 2016, 5, e1067745.	4.6	55
93	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clinical Cancer Research, 2016, 22, 2155-2166.	7.0	211
94	Type I IFNâ€mediated synergistic activation of mouse and human DC subsets by TLR agonists. European Journal of Immunology, 2015, 45, 2798-2809.	2.9	17
95	Primary Human Blood Dendritic Cells for Cancer Immunotherapyâ€"Tailoring the Immune Response by Dendritic Cell Maturation. Biomedicines, 2015, 3, 282-303.	3.2	22
96	Cell tracking using 19F magnetic resonance imaging: Technical aspects and challenges towards clinical applications. European Radiology, 2015, 25, 726-735.	4.5	31
97	Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue. Human Vaccines and Immunotherapeutics, 2015, 11, 1634-1640.	3.3	2
98	Engineering monocyte-derived dendritic cells to secrete interferon-Î± enhances their ability to promote adaptive and innate anti-tumor immune effector functions. Cancer Immunology, Immunotherapy, 2015, 64, 831-842.	4.2	27
99	Immune infiltrates impact on the prediction of prognosis and response to immunotherapy of melanoma patients. Journal of Translational Medicine, 2015, 13, P12.	4.4	2
100	PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by ¹⁹F MRI. Nanomedicine, 2015, 10, 2339-2348.	3.3	34
101	Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets. Cancer Immunology, Immunotherapy, 2015, 64, 1461-1473.	4.2	47
102	Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. OncoImmunology, 2015, 4, e1019197.	4.6	55
103	Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment. Immunobiology, 2015, 220, 243-248.	1.9	13
104	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Frontiers in Immunology, 2014, 5, 165.	4.8	127
105	Dendritic Cell Cross Talk with Innate and Innate-like Effector Cells in Antitumor Immunity: Implications for DC Vaccination. Critical Reviews in Immunology, 2014, 34, 517-536.	0.5	40
106	Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients. American Journal of Ophthalmology, 2014, 158, 939-947.e5.	3.3	53
107	Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. Frontiers in Immunology, 2014, 5, 191.	4.8	71
108	Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. Clinical Cancer Research, 2014, 20, 4390-4399.	7.0	36

#	Article	IF	Citations
109	Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy. OncoImmunology, 2014, 3, e27219.	4.6	3
110	Scientific contributions toward successful cancer immunotherapy in The Netherlands. Immunology Letters, 2014, 162, 121-126.	2.5	1
111	Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics. Clinical Cancer Research, 2014, 20, 2831-2837.	7.0	349
112	Tumoricidal activity of human dendritic cells. Trends in Immunology, 2014, 35, 38-46.	6.8	62
113	Tracking Targeted Bimodal Nanovaccines: Immune Responses and Routing in Cells, Tissue, and Whole Organism. Molecular Pharmaceutics, 2014, 11, 4299-4313.	4.6	42
114	Dendritic Cell-Based Cancer Vaccines. , 2014, , 69-87.		0
115	In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cellular and Molecular Life Sciences, 2013, 70, 2237-2257.	5.4	21
116	Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion. Journal of Immunology, 2013, 191, 5005-5012.	0.8	98
117	Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood, 2013, 121, 459-467.	1.4	154
118	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cellâ€“Based Vaccination. Cancer Research, 2013, 73, 19-29.	0.9	131
119	Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients. Cancer Research, 2013, 73, 1063-1075.	0.9	295
120	An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8Î± Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT. Frontiers in Immunology, 2013, 4, 270.	4.8	6
121	Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells. Clinical Cancer Research, 2013, 19, 1525-1533.	7.0	58
122	In vivo ¹⁹F MRI for Cell Tracking. Journal of Visualized Experiments, 2013, , e50802.	0.3	18
123	Cell tracking using multimodal imaging. Contrast Media and Molecular Imaging, 2013, 8, 432-438.	0.8	19
124	Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination. OncoImmunology, 2013, 2, e24661.	4.6	20
125	Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy. OncoImmunology, 2013, 2, e24440.	4.6	11
126	Naturally circulating dendritic cells to vaccinate cancer patients. OncoImmunology, 2013, 2, e23431.	4.6	27

#	Article	IF	Citations
127	The nature of activatory and tolerogenic dendritic cell-derived signal II. Frontiers in Immunology, 2013, 4, 53.	4.8	91
128	Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts. , 2013, , 71-108.		0
129	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clinical Cancer Research, 2012, 18, 5460-5470.	7.0	86
130	STATing the importance of immune modulation by platinum chemotherapeutics. OncoImmunology, 2012, 1, 234-236.	4.6	31
131	In Vivo Tracking Techniques for Cellular Regeneration, Replacement, and Redirection. Journal of Nuclear Medicine, 2012, 53, 1825-1828.	5.0	19
132	Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. Journal of Clinical Oncology, 2012, 30, 1835-1841.	1.6	112
133	The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood, 2012, 119, 2284-2292.	1.4	217
134	Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. Lancet Oncology, The, 2012, 13, e32-e42.	10.7	219
135	Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters. Cancer Immunology, Immunotherapy, 2012, 61, 2003-2011.	4.2	24
136	Targeted delivery of CpG ODN to CD32 on human and monkey plasmacytoid dendritic cells augments IFNÍ± secretion. Immunobiology, 2012, 217, 1017-1024.	1.9	11
137	Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood, 2012, 120, 3936-3944.	1.4	80
138	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cellâ€"Based Vaccination in Metastatic Melanoma. Cancer Research, 2012, 72, 6102-6110.	0.9	50
139	Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome. BMC Immunology, 2012, 13, 71.	2.2	9
140	Labeling cells for inÂvivo tracking using 19F MRI. Biomaterials, 2012, 33, 8830-8840.	11.4	126
141	Insight into the dynamics, localization and magnitude of antigen-specific immune responses by [18F]FLT PET imaging. OncoImmunology, 2012, 1, 744-745.	4.6	3
142	Potential applications for plasmacytoid dendritic cells in cancer immunotherapy. Immunotherapy, 2012, 4, 979-982.	2.0	7
143	Obstacles on the way to the clinical visualisation of beta cells: looking for the Aeneas of molecular imaging to navigate between Scylla and Charybdis. Diabetologia, 2012, 55, 1247-1257.	6.3	53
144	The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. Cancer Immunology, Immunotherapy, 2012, 61, 1101-1111.	4.2	41

#	Article	IF	Citations
145	Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunology, Immunotherapy, 2012, 61, 1279-1288.	4.2	53
146	Unraveling the human dendritic cell phagosome proteome by organellar enrichment ranking. Journal of Proteomics, 2012, 75, 1547-1562.	2.4	27
147	A largeâ€scale ¹⁹F MRIâ€based cell migration assay to optimize cell therapy. NMR in Biomedicine, 2012, 25, 1095-1103.	2.8	20
148	Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. PLoS ONE, 2012, 7, e51851.	2.5	48
149	Humoral and cellular immune response after influenza vaccination in patients with postcancer fatigue and patients with chronic fatigue syndrome.. Journal of Clinical Oncology, 2012, 30, 9070-9070.	1.6	0
150	Multimodal Imaging of Nanovaccine Carriers Targeted to Human Dendritic Cells. Molecular Pharmaceutics, 2011, 8, 520-531.	4.6	70
151	The lymphoid chemokine CCL21 triggers LFAâ€1 adhesive properties on human dendritic cells. Immunology and Cell Biology, 2011, 89, 458-465.	2.3	15
152	Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Molecular Immunology, 2011, 48, 810-817.	2.2	24
153	Route of Administration Modulates the Induction of Dendritic Cell Vaccineâ€“Induced Antigen-Specific T Cells in Advanced Melanoma Patients. Clinical Cancer Research, 2011, 17, 5725-5735.	7.0	158
154	Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunology, Immunotherapy, 2011, 60, 249-260.	4.2	68
155	DECâ€205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. European Journal of Immunology, 2011, 41, 1014-1023.	2.9	63
156	A novel ¹⁹F agent for detection and quantification of human dendritic cells using magnetic resonance imaging. International Journal of Cancer, 2011, 129, 365-373.	5.1	61
157	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. International Journal of Cancer, 2011, 129, 507-512.	5.1	120
158	IL-4 and IL-13 Alter Plasmacytoid Dendritic Cell Responsiveness to CpG DNA and Herpes Simplex Virus-1. Journal of Investigative Dermatology, 2011, 131, 900-906.	0.7	19
159	Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination. Clinical Cancer Research, 2011, 17, 4541-4549.	7.0	28
160	Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents. Clinical Cancer Research, 2011, 17, 841-848.	7.0	70
161	Early identification of antigen-specific immune responses in vivo by [¹⁸ F]-labeled 3â€²-fluoro-3â€²-deoxy-thymidine ([¹⁸ F]FLT) PET imaging. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18396-18399.	7.1	65
162	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. Journal of Clinical Investigation, 2011, 121, 3100-3108.	8.2	271

#	Article	IF	Citations
163	Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood, 2010, 116, 564-574.	1.4	86
164	Imaging of cellular therapies. Advanced Drug Delivery Reviews, 2010, 62, 1080-1093.	13.7	126
165	Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunology, Immunotherapy, 2010, 59, 1573-1582.	4.2	220
166	Customizable, multi-functional fluorocarbon nanoparticles for quantitative in vivo imaging using 19F MRI and optical imaging. Biomaterials, 2010, 31, 7070-7077.	11.4	120
167	Prognostic significance and mechanism of Treg infiltration in human brain tumors. Journal of Neuroimmunology, 2010, 225, 195-199.	2.3	180
168	19F MRI for quantitative in vivo cell tracking. Trends in Biotechnology, 2010, 28, 363-370.	9.3	252
169	A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. British Journal of Cancer, 2010, 103, 1415-1421.	6.4	60
170	Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients. Clinical Cancer Research, 2010, 16, 5067-5078.	7.0	212
171	Human Plasmacytoid Dendritic Cells Phagocytose, Process, and Present Exogenous Particulate Antigen. Journal of Immunology, 2010, 184, 4276-4283.	0.8	80
172	Cross-Talk between Human Dendritic Cell Subsets Influences Expression of RNA Sensors and Inhibits Picornavirus Infection. Journal of Innate Immunity, 2010, 2, 360-370.	3.8	21
173	Dominant Processes during Human Dendritic Cell Maturation Revealed by Integration of Proteome and Transcriptome at the Pathway Level. Journal of Proteome Research, 2010, 9, 1727-1737.	3.7	45
174	Induction of complete and molecular remissions in acute myeloid leukemia by Wilmsâ€™ tumor 1 antigen-targeted dendritic cell vaccination. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13824-13829.	7.1	341
175	Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 1383-1390.	5.6	131
176	Functional assessment of human dendritic cells labeled for in vivo 19F magnetic resonance imaging cell tracking. Cytotherapy, 2010, 12, 238-250.	0.7	87
177	Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Research, 2010, 30, 5091-7.	1.1	67
178	In situ Expression of Tumor Antigens by Messenger RNAâ€“Electroporated Dendritic Cells in Lymph Nodes of Melanoma Patients. Cancer Research, 2009, 69, 2927-2934.	0.9	56
179	Limited Amounts of Dendritic Cells Migrate into the T-Cell Area of Lymph Nodes but Have High Immune Activating Potential in Melanoma Patients. Clinical Cancer Research, 2009, 15, 2531-2540.	7.0	172
180	DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. Journal of Leukocyte Biology, 2009, 85, 518-525.	3.3	125

#	Article	IF	Citations
181	Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-Oncology, 2009, 11, 394-402.	1.2	203
182	Regulation of MYCNexpression in human neuroblastoma cells. BMC Cancer, 2009, 9, 239.	2.6	28
183	Vaccine-specific local T cell reactivity in immunotherapy-associated vitiligo in melanoma patients. Cancer Immunology, Immunotherapy, 2009, 58, 145-151.	4.2	29
184	Targets for active immunotherapy against pediatric solid tumors. Cancer Immunology, Immunotherapy, 2009, 58, 831-841.	4.2	10
185	Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunology, Immunotherapy, 2009, 58, 1109-1115.	4.2	25
186	Dendritic cell vaccination and immune monitoring. ISBT Science Series, 2009, 4, 18-23.	1.1	0
187	Selective cancer-germline gene expression in pediatric brain tumors. Journal of Neuro-Oncology, 2008, 88, 273-280.	2.9	24
188	Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunology, Immunotherapy, 2008, 57, 1589-1597.	4.2	141
189	Dendritic cell vaccination and immune monitoring. Cancer Immunology, Immunotherapy, 2008, 57, 1559-1568.	4.2	91
190	Intratumoral rhILâ€12 administration in head and neck squamous cell carcinoma patients induces B cell activation. International Journal of Cancer, 2008, 123, 2354-2361.	5.1	76
191	Dendritic cell vaccines in melanoma: From promise to proof?. Critical Reviews in Oncology/Hematology, 2008, 66, 118-134.	4.4	113
192	Tollâ€like receptor signalling on Tregs: to suppress or not to suppress?. Immunology, 2008, 124, 445-452.	4.4	87
193	Maximizing dendritic cell migration in cancer immunotherapy. Expert Opinion on Biological Therapy, 2008, 8, 865-874.	3.1	59
194	Activation of Human Plasmacytoid Dendritic Cells by TLR9 Impairs FcÎ³RII-Mediated Uptake of Immune Complexes and Presentation by MHC Class II. Journal of Immunology, 2008, 181, 5219-5224.	0.8	24
195	Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-Î± production. Blood, 2008, 111, 4245-4253.	1.4	230
196	Relevance of DC-SIGN in DC-induced T cell proliferation. Journal of Leukocyte Biology, 2007, 81, 729-740.	3.3	24
197	Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. International Journal of Cancer, 2007, 120, 67-74.	5.1	70
198	Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediatric Blood and Cancer, 2007, 49, 924-927.	1.5	10

#	Article	IF	Citations
199	Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nature Reviews Immunology, 2007, 7, 790-802.	22.7	678
200	Potential applications of dendritic cells. ISBT Science Series, 2007, 2, 264-271.	1.1	0
201	In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunology, Immunotherapy, 2007, 56, 1667-1676.	4.2	24
202	Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilmsâ€™ Tumor Protein WT1: A Phase I/II Trial.. Blood, 2007, 110, 158-158.	1.4	2
203	Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination. Nuclear Medicine and Biology, 2006, 33, 453-458.	0.6	14
204	Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. International Journal of Cancer, 2006, 120, 978-984.	5.1	82
205	Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Annals of Oncology, 2006, 17, 974-980.	1.2	85
206	Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after FcÎ³RII-mediated uptake. Journal of Experimental Medicine, 2006, 203, 1629-1635.	8.5	92
207	Phenotypical and Functional Characterization of Clinical-Grade Dendritic Cells. , 2005, 109, 113-126.		28
208	Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized antiâ€“DC-SIGN antibody. Blood, 2005, 106, 1278-1285.	1.4	265
209	Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nature Biotechnology, 2005, 23, 1407-1413.	17.5	791
210	Migration of dendritic cell based cancer vaccines: in vivo veritas?. Current Opinion in Immunology, 2005, 17, 170-174.	5.5	135
211	Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor. Clinical Cancer Research, 2005, 11, 1899-1909.	7.0	80
212	Immunomonitoring Tumor-Specific T Cells in Delayed-Type Hypersensitivity Skin Biopsies After Dendritic Cell Vaccination Correlates With Clinical Outcome. Journal of Clinical Oncology, 2005, 23, 5779-5787.	1.6	174
213	Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results. Annals of Oncology, 2004, 15, iv145-iv151.	1.2	50
214	Dendritic cell immunotherapy: mapping the way. Nature Medicine, 2004, 10, 475-480.	30.7	896
215	The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. European Journal of Immunology, 2003, 33, 532-538.	2.9	336
216	Peptide Fine Specificity of Anti-Glycoprotein 100 CTL Is Preserved Following Transfer of Engineered TCRÎ±Î² Genes Into Primary Human T Lymphocytes. Journal of Immunology, 2003, 170, 2186-2194.	0.8	138

#	Article	IF	Citations
217	Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Research, 2003, 63, 12-7.	0.9	659
218	Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clinical Cancer Research, 2003, 9, 5091-100.	7.0	235
219	Phenotypical and Functional Characterization of Clinical Grade Dendritic Cells. Journal of Immunotherapy, 2002, 25, 429-438.	2.4	140
220	Vaccination of Patients With Metastatic Renal Cell Carcinoma With Autologous Dendritic Cells Pulsed With Autologous Tumor Antigens in Combination With Interleukin-2: A Phase 1 Study. Journal of Immunotherapy, 2002, 25, 500-508.	2.4	99
221	Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-dr molecules to CD4+ T lymphocytes. International Journal of Cancer, 2002, 100, 441-444.	5.1	49
222	Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endotheliumin situin patients with erythroderma, mycosis fungoides and atopic dermatitis. Journal of Cutaneous Pathology, 2000, 27, 436-440.	1.3	32
223	Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore. European Journal of Immunology, 1993, 23, 956-960.	2.9	123
224	Eosinophils and Cytokines. , 1993, 43, 197-208.		10
225	‹scp›PDâ€Ł1‹/scp› in gestational trophoblastic disease: an antibody evaluation. Acta Obstetricia Et Gynecologica Scandinavica, 0, , .	2.8	1
226	Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome. Cancer Immunology, Immunotherapy, 0, , .	4.2	1